Two funds hold 8.14 million Arbutus Biopharma (ABUS) shares under the same investment manager.
Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported an amended beneficial-ownership stake of 4.1% in Arbutus Biopharma (ABUS), totaling 8,143,994 shares as of September 30, 2026. These shares are held across two funds, Two Seas Global (Master) Fund LP and Two Seas LNP Opportunities (Master) Fund LP, with Two Seas Capital LP serving as the investment manager with sole voting and dispositive power. The reported percentage is based on 199,275,907 ABUS common shares outstanding.
Nomura reports a passive stake above 5% in Arbutus Biopharma (ABUS).
Nomura Global Financial Products, Inc., a subsidiary of Nomura Holdings, Inc., has reported a beneficial ownership of 14,512,000 common shares, representing 7.3% of Arbutus Biopharma Corp (ABUS). This passive investment disclosure was made via a SCHEDULE 13G filing with the SEC. The percentage is calculated based on 199,275,907 common shares outstanding as of September 30, 2026.
Arbutus Biopharma Corp (I9DN.MU) Seasonal returns chart - Yahoo Finance
The article provides a seasonal returns chart for Arbutus Biopharma Corp (I9DN.MU) on Yahoo Finance, displaying the average monthly price return from 2016 to 2026. It includes current stock information, market indices, and navigation options for various financial data.
Arbutus Biopharma Updates Corporate Presentation, Reports $104.6M in Cash
Arbutus Biopharma has released an updated corporate presentation, revealing a cash and cash equivalents balance of $104.6 million as of October 31, 2026. The company also highlighted positive results from its hepatitis B pipeline, including a 46% functional cure rate across Phase 2a trials and is evaluating plans for a potential Phase 2b imdusiran trial. Additionally, its AB-101 presentation showcased full PD-L1 receptor occupancy in a majority of healthy subjects during Phase 1.
A $67.3M Genevant dividend factors into Arbutus Biopharma (ABUS) Q3 earnings.
Arbutus Biopharma reported a Q3 2026 net income of $59.1 million, a significant improvement from a net loss in the prior year, largely driven by a $67.3 million dividend from Genevant. This dividend is part of a larger $950 million noncontingent settlement payment from Moderna to Arbutus and Genevant related to patent infringement litigation. The company also detailed its clinical progress for imdusiran and AB-101 in treating chronic hepatitis B and its ongoing patent lawsuits against Pfizer/BioNTech.
Form 8K Arbutus Biopharma Corp For: 10 November By Investing.com
Investing.com reported that Arbutus Biopharma Corp filed a Form 8K on November 10th. The article briefly mentions the stock symbol ABUS and its price performance, indicating a -3.01% change. This filing provides important financial and operational updates for investors.
Arbutus Biopharma earnings beat by $0.32, revenue fell short of estimates
Arbutus Biopharma (NASDAQ: ABUS) reported third-quarter EPS of $0.300, exceeding analyst estimates by $0.32, but revenue of $300K fell short of the consensus estimate of $681K. The company's stock price closed at $3.72, down over 20% in the last 3 and 12 months. InvestingPro rates Arbutus Biopharma's financial health as "great performance."
Form 8K Arbutus Biopharma Corp For: 10 November By Investing.com
This article reports on Arbutus Biopharma Corp's Form 8K filing for November 10. The 8K filing is a crucial document that public companies must submit to the U.S. Securities and Exchange Commission (SEC) to announce significant events that shareholders should know about. The article highlights the company's stock symbol ABUS.
ABUS: Arbutus recognizes $178.4M settlement revenue in nine months
Arbutus Biopharma Corporation (ABUS) reported a significant increase in nine-month revenue for 2026, primarily due to recognizing $178.4 million from a noncontingent settlement payment. This uplift was partially offset by $9.6 million of previously deferred Qilu revenue recognized in 2025. This settlement represents a one-time revenue item rather than recurring sales.
BlackRock reports sole voting power over 14M Arbutus Biopharma (ABUS) shares.
BlackRock, Inc. has filed an amended beneficial-ownership report for Arbutus Biopharma Corp (ABUS), disclosing beneficial ownership of 14,331,732 common shares, which represents 7.2% of the class as of September 30, 2026. The report indicates BlackRock holds sole voting power over 14,033,488 shares and sole dispositive power over all 14,331,732 shares. While various persons may receive dividends or sale proceeds, no individual's interest exceeded 5% of Arbutus's outstanding common shares.
Arbutus Biopharma Clears FDA Clinical Hold on AB-101 IND
Arbutus Biopharma has received clearance from the FDA to proceed with further U.S. clinical development of its oral PD-L1 inhibitor, AB-101, after the clinical hold on its IND application was lifted. The company is now evaluating the next steps for the continued development of AB-101, which previously showed good tolerability and promising results in a Phase 1a/1b trial for healthy subjects and chronic Hepatitis B Virus patients.
Why Is Arbutus Biopharma Stock Trading Higher Today? - Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma's stock is trading higher after the FDA lifted a three-year clinical hold on its Investigational New Drug (IND) application for AB-101, a potential hepatitis B treatment. The company will now evaluate further development for AB-101, which showed positive results in its Phase 1 clinical trial. Additionally, Arbutus announced plans for a $230 million stock repurchase, funded by a recent settlement with Moderna Inc.
Form 8K Arbutus Biopharma Corp For: 22 October By Investing.com
This article announces that Arbutus Biopharma Corp filed a Form 8K on October 22, 2026. The filing is a standard regulatory announcement for publicly traded companies. The content provides basic information about the filing without further details.
Form 8K Arbutus Biopharma Corp For: 22 October By Investing.com
The article reports that Arbutus Biopharma Corp filed a Form 8K on October 22, 2026. This filing is a significant event for investors, as Form 8K is used to announce major events that shareholders should know about. The article briefly mentions the stock symbol ABUS and its current performance.
FDA lifts clinical hold on Arbutus Biopharma's AB-101 drug candidate
The FDA has lifted the clinical hold on Arbutus Biopharma's AB-101, an oral PD-L1 inhibitor for chronic hepatitis B virus infection. The company is now evaluating the next steps for the drug's continued development. AB-101 has shown promising results in Phase 1a/1b trials, including high receptor occupancy and hepatitis B surface antigen decline in some patients.
Arbutus Biopharma Clears FDA Clinical Hold on AB-101 IND
Arbutus Biopharma (ABUS) has announced that the FDA has lifted the clinical hold on its Investigational New Drug (IND) application for AB-101, an oral PD-L1 inhibitor. This allows the company to pursue further U.S. clinical development of the drug. AB-101 previously completed a Phase 1a/1b trial, which demonstrated it was generally well-tolerated and showed promising signs of efficacy in some chronic Hepatitis B Virus (cHBV) patients.
Form 8K Arbutus Biopharma Corp For: 22 October By Investing.com
This article reports on Arbutus Biopharma Corp's Form 8K filing for October 22, 2026. The brief announcement provides no specific details about the content of the filing but references the company's stock symbol ABUS. It appears to be a standard notification of a regulatory filing.
The FDA lifted a hold on Arbutus' experimental oral hepatitis B drug.
Arbutus Biopharma announced that the FDA has lifted the clinical hold on its Investigational New Drug (IND) application for AB-101, an oral PD-L1 inhibitor aimed at treating chronic hepatitis B. This decision allows the company to pursue further clinical development in the United States. Previous Phase 1a/1b trial results indicated that AB-101 was generally well-tolerated, showing high receptor occupancy and hepatitis B surface antigen declines in some patients.
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
Arbutus Biopharma Corporation announced that the FDA has lifted the clinical hold on its Investigational New Drug (IND) application for AB-101, an oral PD-L1 inhibitor. This allows Arbutus to proceed with additional clinical development for AB-101 in the United States. AB-101 is being developed to activate HBV-specific immune responses and has shown promising safety and efficacy signals in a Phase 1a/1b clinical trial.
Form 4 Arbutus Biopharma Corp For: 10 October By Investing.com
This article reports on a Form 4 filing for Arbutus Biopharma Corp (ABUS) related to October 10. The filing, crucial for disclosing insider transactions, was published by Investing.com. No specific details about the transaction are provided within the article.
Form 4 Arbutus Biopharma Corp For: 10 October By Investing.com
This article announces the filing of Form 4 for Arbutus Biopharma Corp, pertaining to activities on October 10th. It notes the stock symbol ABUS and its current performance. The content is primarily a concise announcement from Investing.com.
Form 4 Arbutus Biopharma Corp For: 10 October By Investing.com
This article announces the filing of Form 4 for Arbutus Biopharma Corp (ABUS) on October 10. Form 4 is a document that must be filed with the SEC whenever there is a material change in the holdings of company insiders. The article itself contains no further details beyond this announcement.
Morgan Stanley reports owning more than 10% of Arbutus Biopharma (ABUS) in an amendment.
Morgan Stanley has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 12.2% of Arbutus Biopharma Corp (ABUS) common shares, totaling 18,682,708 shares. This includes 11.3% owned by Morgan Stanley Investment Management Inc. The filing details shared voting and dispositive power over these shares, outlining the extent of Morgan Stanley's influence over ABUS.
Arbutus CFO Tuan Nguyen Sells 48,081 Shares in Company Tender Offer
Arbutus Biopharma Corp's CFO, Tuan Nguyen, sold 48,081 common shares at $5 per share on October 1, 2026, as part of the company's tender offer. This transaction was disclosed in a Form 4 filing on October 7, 2026. Following the sale, Nguyen's direct beneficial ownership in the company stands at 111,882 common shares.
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%.
Arbutus Biopharma announced it accepted 46 million common shares at $5.00 per share in its issuer tender offer, totaling up to $230 million. Roivant Sciences Ltd. tendered 8,967,383 shares, receiving approximately $44.8 million, and subsequently retains beneficial ownership of about 19.5% of Arbutus's outstanding shares. The offer, which included a proportionate tender option, expired on September 29, 2026.
Form 13D/A Arbutus Biopharma Corp For: 5 October By Investing.com
This article announces the filing of Form 13D/A for Arbutus Biopharma Corp on October 5th. It is a very brief news item from Investing.com, providing only the title and publication date without further details about the filing's content. The rest of the page is filled with general market data, news headlines, and navigational links from the Investing.com website.
Form 13D/A Arbutus Biopharma Corp For: 5 October By Investing.com
This article reports on a Form 13D/A filing for Arbutus Biopharma Corp, dated October 5th. It is a brief news item published by Investing.com, likely notifying investors of a significant ownership disclosure. The article was published on October 6, 2026, at 03:32 UTC.
Form 4 Arbutus Biopharma Corp For: 5 October By Investing.com
This article reports on the filing of a Form 4 for Arbutus Biopharma Corp, specifically for activity on October 5th. It mentions the company's stock symbol ABUS and its daily performance, indicating a -4.07% change. The content primarily focuses on this financial filing and includes general stock market data and other news headlines.
Form 4 Arbutus Biopharma Corp For: 5 October By Investing.com
This article reports on a Form 4 filing for Arbutus Biopharma Corp (ABUS) related to October 5th. Form 4s are filed with the SEC to disclose changes in beneficial ownership of a company's securities by insiders. The article indicates a slight negative price change for ABUS at the time of publication.
Arbutus Biopharma Corporation (ABUS) Stock Price, News, Quote & History
This article provides detailed financial information for Arbutus Biopharma Corporation (ABUS), including its current stock price, historical data, key statistics, and an overview of its clinical-stage pipeline. It highlights the company's focus on developing therapeutics for chronic Hepatitis B virus and its financial performance, including earnings trends and analyst ratings.
The share offer capped at $230M has expired. Arbutus (ABUS) announces final results.
Arbutus Biopharma Corporation (ABUS) has announced the final results of its modified Dutch auction tender offer. The offer, which aimed to repurchase common shares for an aggregate price not exceeding US$230 million at prices ranging from US$5.00 to US$5.75 per share, expired on September 29, 2026. This announcement confirms the completion of the share repurchase program.
An up-to-$230M share offer expired; Arbutus Biopharma (ABUS) announced preliminary results.
Arbutus Biopharma (ABUS) announced the preliminary results of its issuer tender offer, which expired on September 29, 2026, at 5:00 p.m. New York City time. The company had offered to repurchase common shares for an aggregate purchase price not exceeding US$230 million, at a price range of US$5.00 to US$5.75 per share in cash. This announcement was made via a press release on September 30, 2026, and an amendment to its Schedule TO filing.
10 Health Care Stocks With Whale Alerts In Today’s Session - Arbutus Biopharma (NASDAQ:ABUS), Novo Nordis
This article identifies ten healthcare stocks that showed significant options activity, known as "whale alerts," during today's trading session. It details specific put and call options trades for companies like Arbutus Biopharma (ABUS), Novo Nordisk (NVO), and AbbVie (ABBV), along with their sentiment, expiration dates, strike prices, and trade volumes. The piece aims to help traders spot potential opportunities by tracking unusual option trading volumes.
Arbutus Biopharma Corp. Research & Ratings | I9DN
This article provides research and ratings for Arbutus Biopharma Corp. (I9DN), listed on the Frankfurt market. It details analyst ratings, key financial metrics, company profile, and upcoming earnings reports, including yearly and quarterly estimates.
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com
This article is a Form 4 filing for Arbutus Biopharma Corp, dated September 23, 2026. Form 4 is a U.S. Securities and Exchange Commission (SEC) form that must be filed by company insiders to report transactions in their company's stock. The article itself does not contain details of the transactions but serves as a notification of the filing.
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com
This article from Investing.com reports on a Form 4 filing for Arbutus Biopharma Corp (ABUS) related to September 23. Form 4 filings are legally required documents by the SEC for insiders of a company to report changes in their ownership of the company's stock. The article provides minimal detail beyond the announcement of the filing itself.
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com
This article from Investing.com announces the filing of a Form 4 for Arbutus Biopharma Corp on September 23. The Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) when there is a change in the beneficial ownership of a company's stock by insiders. The article provides the ticker symbol ABUS and notes that it experienced a -0.61% change.
Arbutus Biopharma Corp (ABUS) Peer Comparison – Compare with Others
This article provides a peer comparison for Arbutus Biopharma Corp (ABUS) against several other pharmaceutical companies, including Bausch Health Companies (BHC), Cronos Group Inc. (CRON), Sundial Growers - ADR, and Canopy Growth Corp (CGC). It presents detailed financial metrics across market capitalization, revenue, net profit, various ratios (P/E, P/B, cashflow, profitability, growth, valuation, solvency, and operating efficiency), allowing for a direct comparison of their financial health and performance. The data helps investors evaluate ABUS relative to its competitors in the healthcare and pharmaceutical sector.
An 8% holder now reports a passive stake in Arbutus Biopharma (ABUS)
Whitefort Capital and its affiliates have reported a passive 8.0% beneficial stake in Arbutus Biopharma (ABUS) through a Schedule 13G filing. This indicates they no longer seek to influence the company's control, a shift from a previous Schedule 13D filing. The group beneficially owns 15,794,261 common shares, representing 8.0% of the outstanding shares as of September 4, 2026.
Why Is Arbutus Biopharma Stock Gaining Friday? - Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma (NASDAQ:ABUS) stock rose after the company announced a modified Dutch auction tender offer to repurchase up to $230 million of its common stock at $5-$5.75 per share. This buyback is being funded by the March 2026 settlement with Moderna, from which Arbutus received $178 million. Arbutus continues patent litigation against Pfizer and BioNTech and is developing treatments for chronic hepatitis B virus.
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
Arbutus Biopharma (ABUS) stock surged over 10% in pre-market trading after the company announced its intent to repurchase up to $230 million of its common shares. The company also recently filed international lawsuits to enforce patents protecting its LNP technology against Pfizer and BioNTech. During Q2, Arbutus Biopharma reported revenues of $1.01 million, exceeding estimates, and ended the quarter with $92.6 million in cash, cash equivalents, and marketable securities.
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Biopharma Corporation has launched a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares. The offer allows shareholders to tender shares at a price between US$5.00 and US$5.75, aiming to provide liquidity and increase non-tendering shareholders' proportional ownership. This initiative follows the company's receipt of approximately US$178 million from a patent infringement settlement with Moderna.
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Arbutus Biopharma Corporation announced plans to commence a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares, with prices ranging from US$5.00 to US$5.75 per share. The company intends to fund the offer through cash on hand, attributing this decision to recent financial proceeds from its March 2026 settlement with Moderna regarding its lipid nanoparticle technology. Arbutus plans to continue enforcing its intellectual property rights against infringers like Pfizer and BioNTech.
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares
Arbutus Biopharma has initiated a modified "Dutch Auction" tender offer to repurchase up to $230 million of its common shares, with prices ranging from $5.00 to $5.75 per share. The offer begins on August 24, 2026, and is set to expire on September 29, 2026. This move follows a significant cash inflow from a patent infringement settlement with Moderna, aiming to provide liquidity to shareholders and potentially increase the ownership percentage for non-participating shareholders.
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Biopharma Corporation has launched a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares, with a price range of US$5.00 to US$5.75 per share. The offer, which expires on September 29, 2026, allows shareholders to tender shares at a specified auction price, a purchase price to be determined, or proportionately to maintain their ownership. This move follows Arbutus receiving a US$178 million payment from a settlement with Moderna, and the company believes the offer provides an efficient way to return value to shareholders while allowing some to retain their investment.
Arbutus Biopharma stock surges on $230M buyback plan By Investing.com
Arbutus Biopharma (NASDAQ:ABUS) shares surged over 10% in premarket trading after announcing a plan to repurchase up to $230 million of its common shares through a modified Dutch auction tender offer. The buyback is funded by the company's cash on hand, following a settlement with Moderna in March 2026 and an initial payment received in July 2026. The company intends to continue enforcing its lipid nanoparticle technology rights against other infringers like Pfizer and BioNTech.
Arbutus Biopharma (ABUS) 10K Form and Latest SEC Filings 2026
This article provides an overview of Arbutus Biopharma's (ABUS) SEC filings, highlighting that the company has submitted over 366 documents since 2017. It details recent filings including an 8-K current report and a 10-Q quarterly report, and explains the importance of various SEC filing types like 10-K, 10-Q, and 8-K for investors. The article emphasizes that these filings are primary sources of verified financial data for evaluating a company's financial position.
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma stock surged Friday following the announcement of a planned $230 million share repurchase program through a modified Dutch auction tender offer. The company aims to offer shareholders between $5 and $5.75 per share, funding the buyback with cash on hand, partly derived from a recent settlement with Moderna. Arbutus also continues patent litigation against Pfizer and BioNTech and is developing treatments for chronic hepatitis B.
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback
Arbutus Biopharma Corp (ABUS) has announced its intention to launch a modified "Dutch auction" tender offer to repurchase up to US$230 million of its common shares. The proposed price range for shareholders to tender their shares is US$5.00 to US$5.75 per share. The company noted that the offer has not yet commenced and its terms may change.
Why is Arbutus Biopharma stock surging today?
Arbutus Biopharma (ABUS) stock surged nearly 9.8% after the company announced a modified Dutch auction tender offer to repurchase up to $230 million of its common shares. This buyback is financed by a $950 million payment received from Moderna in July 2026, stemming from a patent infringement settlement. The announcement, coupled with the strengthened cash position, drove the stock to a fresh 52-week high.